%0 Journal Article
%A del Carmen Alamo, Ma
%A Ochenduszko, Sebastian
%A Crespo, Guillermo
%A Corral, Monica
%A Oramas, Juana
%A Sancho, Pilar
%A Medina, Javier
%A Garicano, Fernando
%A Lopez, Pedro
%A Campos Balea, Begona
%A Rodriguez Garzotto, Analia
%A Munoz-Couselo, Eva
%T Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
%D 2021
%@ 1178-6930
%U https://hdl.handle.net/10668/26599
%X Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAF(v600) mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR
%K vemurafenib
%K cobimetinib
%K BRAF
%K metastatic melanoma
%K durable response
%K clinical practice
%K Combination
%K Mortality
%K Outcomes
%K Therapy
%K Cohort
%K V600e
%~